Premium
Advanced renal cell carcinoma in which a combination of IFN‐α and meloxicam was thought to be effective
Author(s) -
YOSHINO SHUJI,
OKABE TADASHI
Publication year - 2003
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.2003.00566.x
Subject(s) - medicine , meloxicam , renal cell carcinoma , alpha interferon , metastasis , intramuscular injection , carcinoma , lesion , malaise , alpha (finance) , urology , surgery , interferon , immunology , cancer , construct validity , patient satisfaction
An 83‐year‐old man with left renal cell carcinoma (RCC; pT4N0M0) was treated with postoperative combined subcutaneous injection therapy of alpha interferon (IFN‐α) and IFN gamma‐1a (IFN‐γ‐1a). Metastasis to the pleura occurred 3 months after surgery. The metastatic lesion grew while the treatment was changed to intramuscular injection of IFN‐α‐2b due to the presence of severe general malaise, which seemed to be caused by IFN‐α and IFN‐γ therapy. As melosalgia associated with sciatica was also severe, treatment with meloxicam, which is known as a potent cyclooxigenase‐2 inhibitor among commercially available non‐steroidal anti‐inflammatory drugs, was combined, resulting in significant improvement in activity of daily life, 43.2% decrease in the size of the pleural metastasis and complete regression of retroperitoneal residual tumor.